Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment...
Month: January 2025
Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections
Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327GFull data...
Hepion Pharmaceuticals Announces $9.0 Million Public Offering
EDISON, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been...
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Live webcast on Wednesday, January 29th at 2:20 PM ET Carlsbad, CA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc....
Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
Streamline Health® Announces Fourth CommunityWorks RevID Contract With Kentucky-Based Health System
Oracle Health partnership enables 120-bed Kentucky-based health system to leverage RevID’s automated charge reconciliation to improve financial performanceATLANTA, Jan. 22,...
Rakovina Therapeutics Comments on $500 Billion AI Infrastructure Investment and Its Implications for Healthcare Innovation
VANCOUVER, British Columbia, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront...
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population...
SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial
DENVER, Jan. 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary...
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
- ARCATUS®, Branded as XIPERE® in the U.S., is the First Globally Approved Suprachoroidal Therapy - - Continued Global Expansion...
IVOS Medical Receives Phase II SBIR Award from the National Institutes of Health for $1.9M
IRVINE, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IVOS Medical, Inc., a startup medical device specializing company in airway management,...
IVOS Medical Announces BOSS G4™ Video Laryngoscope Sheath Designed to Improve Intubation Safety in High-Risk Patients
Innovative Device Provides Clear Vision, Maintains Continuous Oxygen Delivery, and Clears Aspirate and Debris During IntubationIRVINE, Calif., Jan. 22, 2025...
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America
REHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical...
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study
--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people...
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor...
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
Company Announcement Net sales of DARZALEX® in 2024 totaled USD 11,670 millionGenmab receives royalties on worldwide net sales from Johnson...
Greenwich LifeSciences Provides Update on Commercial Manufacturing
STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...